Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and Safety of PYLERA™ (Bismuth Subcitrate Potassium, Metronidazole, and Tetracycline Hydrochloride) With Omeprazole Given x 10 Days in Subjects Who Failed Treatment for Eradication of Helicobacter pylori [Efficacia e sicurezza della somministrazione di PYLERA` (bismuto subcitrato potassio, metronidazolo e tetraciclina cloridrato) con omeprazolo per un periodo di 10 giorni in soggetti refrattari a trattamenti di eradicazione dell'Helicobacter pylori].

Next Previous
Trial Profile

Efficacy and Safety of PYLERA™ (Bismuth Subcitrate Potassium, Metronidazole, and Tetracycline Hydrochloride) With Omeprazole Given x 10 Days in Subjects Who Failed Treatment for Eradication of Helicobacter pylori [Efficacia e sicurezza della somministrazione di PYLERA` (bismuto subcitrato potassio, metronidazolo e tetraciclina cloridrato) con omeprazolo per un periodo di 10 giorni in soggetti refrattari a trattamenti di eradicazione dell'Helicobacter pylori].

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 07 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tripotassium dicitrato bismuthate/tetracycline/metronidazole (Primary) ; Omeprazole
  • Indications Helicobacter pylori infections
  • Focus Therapeutic Use
  • Sponsors Adare Pharmaceuticals

    • Most Recent Events

    • 07 Oct 2021 This trial is completed in spain (global end of the trial 2013-01-18) as reported by European Clinical Trials Database record.
    • 19 May 2012 Planned number of patients changed from 12 to 50 as reported by European Clinical Trials Database.
    • 19 May 2012 Company added in association field as reported by European Clinical Trials Database.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top